John Glasspool

Cambridge, Massachusetts, United States
John Glasspool is CEO, President and member of the Board of Directors of Anthos Therapeutics. He is also a member of the Board of Directors of Relmada Therapeutics Inc (Nasdaq: RLMD) and of Dalcor Corporation. Before joining Anthos Therapeutics, John held senior roles at Novartis including as the Global Head of the Cardiovascular and Metabolic Diseases franchise; Region Head for Europe; Global Head of Pricing & Market Access, as well as many other senior leadership roles. Before joining Anthos, John also held senior roles at Baxalta. John has served as a Member of the Board of BIO from 2014 to 2016, and is currently a Member of the Board, BIO Emerging Companies Section.
Speaking In
1:45 PM - 2:45 PM (PDT)
Tuesday, June 14
Hemostasis and thrombosis are believed to be so intricately linked that any strategies that reduce…